From the trastuzumab era to new target therapies: beyond revolution.
Barni
S
S
Division of Medical Oncology, Azienda Ospedaliera Treviglio-Caravaggio, Bergamo, Italy. sandro.barni@ospedale.treviglio.bg.it
Petrelli
F
F
Cabiddu
M
M
Cazzaniga
M E
ME
Cremonesi
M
M
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic / Q000379:methods / Q000639:trends*; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D005260:Female; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000639:trends*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068878:Trastuzumab